Our Company

Prof. Nava Zisapel (Emeritus, Tel Aviv University), founder and CEO of Neurim Pharmaceuticals, is a renown neuroscientist with research focus on melatonin, sleep, and neurosecretion. Professor Zisapel is the principal author of over 200 papers in peer-reviewed journals and principal inventor of over 60 patents. She led the development and commercialization of the company’s first drugs and is deeply involved in discovering and developing new medicines that hold promise for patients with CNS-related conditions.

Since joining Neurim Pharmaceuticals in 2011, Adi Zisapel has served in several commercial roles, becoming the company’s Chief Commercial Officer in 2014. Her focus on developing the business brings impact both on Neurim's strategic partnerships worldwide and on the successful launch and performance of Neurim’s products, resulting in significant YoY growth. Adi has broadened Neurim’s global marketing, market access and sales activities, and is responsible for the development of strategic partner alliances while overseeing Neurim’s global subsidiaries. Adi holds a BSc in biotechnology engineering from the Technion (Israel Institute of Technology).

Nitza Lifshitz joined Neurim in 2023 as VP Finance and Operations. Nitza has more than 20 years of experience in senior financial management positions. Nitza brings us deep understanding and experience in financial planning, accounting and implementation of processes and high-end technologies, to achieve measurable and sustainable results. Nitza is a certified public accountant with an MBA degree (magna cum laude), a major in Accounting & Finance from Tel- Aviv university.

Since 1997, Dr. Tali Nir has been Neurim's VP for Clinical and Regulatory Affairs, leading its global product registration and clinical development. During this time Tali has acted in various CNS fields including insomnia in adults and in the pediatric ASD population, Alzheimer’s disease, ocular hypertension, pain and sleep apnea. She has led phase 1-4 clinical studies of Neurim Pharmaceuticals’ products and pipeline, including Circadin and Slenyto, and their worldwide regulatory registration. Tali Nir is a Doctor of Veterinary Medicine with a degree from the Hebrew University of Jerusalem in Israel.

Yafi Outmezguine joined Neurim in 2023 as VP Commercial operation. Yafi has more than 26 years of experience in the field of pharmaceuticals and medical devices in which she held successfully various managerial positions in Israel and around the world. Yafi is responsible for Neurim’s commercial, sales and operation strategy, business development and market access initiatives. Yafi holds a BSc in biotechnology engineering from the Technion (Israel Institute of Technology).